Equities

Lotus Pharmaceutical Co Ltd

1795:TAI

Lotus Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)281.50
  • Today's Change-4.00 / -1.40%
  • Shares traded2.10m
  • 1 Year change+14.66%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

  • Revenue in TWD (TTM)17.59bn
  • Net income in TWD4.33bn
  • Incorporated1966
  • Employees1.10k
  • Location
    Lotus Pharmaceutical Co Ltd17FNo. 277, Songren Road, Xinyi DistrictTAIPEI 110TaiwanTWN
  • Phone+886 227005908
  • Fax+886 227008286
  • Websitehttps://www.lotuspharm.com.tw/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
YungShin Global Holding Corp7.82bn1.03bn15.48bn1.57k15.042.0210.971.983.863.8629.3528.780.62731.505.87--9.036.6412.8910.2043.4345.1114.4010.451.50--0.130970.94-3.88-1.33-1.403.34-29.000.893
ScinoPharm Taiwan Ltd3.49bn399.39m18.70bn1.01k46.941.7921.225.350.50380.50384.4113.200.29921.208.63--3.422.333.642.5139.5341.0911.439.106.64--0.0608109.25-2.39-2.00-18.73-8.3116.90-9.35
Lotus Pharmaceutical Co Ltd17.59bn4.33bn75.85bn1.10k17.343.7413.524.3116.4716.4766.8976.240.50141.942.58--12.359.1715.0411.3656.3949.3224.6315.991.89--0.380926.7715.8921.4135.91110.4452.35--
Bora Pharmaceuticals Co Ltd16.71bn3.90bn80.35bn91.0020.916.6816.484.8137.3137.31158.18116.690.49862.372.37--11.9211.2719.2618.6645.0839.2523.9118.551.405.930.573637.8235.3159.57117.7046.91128.2064.83
Data as of Nov 22 2024. Currency figures normalised to Lotus Pharmaceutical Co Ltd's reporting currency: Taiwan Dollar TWD

Institutional shareholders

6.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 06 Nov 20245.01m1.89%
Norges Bank Investment Managementas of 30 Jun 20242.35m0.88%
Capital Investment Trust Corp.as of 30 Sep 20242.18m0.82%
Uni-President Asset Management Corp.as of 30 Sep 20241.97m0.74%
BlackRock Fund Advisorsas of 07 Nov 20241.42m0.54%
Dimensional Fund Advisors LPas of 07 Nov 20241.39m0.52%
Lazard Asset Management LLCas of 31 Mar 20241.31m0.49%
Yuanta Securities Investment Trust Co., Ltd.as of 08 Nov 2024513.24k0.19%
BlackRock Advisors (UK) Ltd.as of 08 Nov 2024376.31k0.14%
State Board of Administration of Florida Retirement Systemas of 30 Jun 2024263.48k0.10%
More ▼
Data from 30 Jun 2024 - 15 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.